FORT WORTH, Texas, Nov. 20 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (WNDM), announced today a published case demonstrating the efficacy of their advanced wound care collagen product, CellerateRx(R). The case was presented in the November/December 2008 issue of Podiatry Management in the special section, Diabetic Wound Care Management on the Leading Edge: Case Presentations from APWCA, APWCA Case #1: Using Combined Treatment Modalities for Successful Wound Healing. The case was by Jane Fore, MD, a board certified internist and certified wound care specialist, whose practice is totally dedicated to the healing of challenging wounds.
"We are very excited about the unsolicited case published in this month's edition of Podiatry Management," states Cathy Bradshaw, President of Wound Care Innovations. "Diabetic foot wounds with infections can be complicated and can require multiple approaches to treatment. This case demonstrates the biocompatibility of CellerateRx(R) in supporting the successful take of living skin equivalents and the delivery of antimicrobials when used in combinational therapies. The article further reports CellerateRx's(R) effectiveness in treating tunneling wounds, and is easy to use. Packing and unpacking these tunneling wounds can be very painful for the patient. CellerateRx(R) is biodegradable and does not need to be removed from the wound. We are delighted to be able to provide to the market a unique, patented advanced wound care collagen product to assist in the management of these difficult wounds."
Diabetic wounds are problematic for patients and a drain on the healthcare industry. In the United States, it is estimated that 15-20% of diabetics will develop a foot ulcer in their lifetime and that 14-24% of these ulcers will result in amputations. Every 30 seconds a leg is lost to diabetes somewhere in the world.
|SOURCE Wound Management Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved